Journal of Neuro-Oncology

, Volume 7, Issue 3, pp 249–254

Immunophenotypic profile of CNS lymphoma: A review of eighteen cases

  • R. Bashir
  • A. Freedman
  • N. Harris
  • K. Bain
  • L. Nadler
  • F. Hochberge
Article

Summary

The cell surface antigenic phenotype of 18 cases of central nervous system (CNS) large-cell lymphoma (14 primary, four secondary) was examined by an immunoperoxidase technique using antibodies that identify B cell restricted and associated antigens. All cases were shown to be of B cell origin by virtue of the expression of monotypic immunoglobulin (Ig) (16 IgM, two IgG) and the pan B cell antigen B1 ( CD20). A panel of monoclonal antibodies directed against B cell restricted and associated activation antigens including B5, Blast-1, Blast-2 (CD23), BB1, interleukin 2 receptor (IL2R, CD25), T9 (transferrin receptor) and TNK-TAR (4F2) was used on 12 of the cases. The majority expressed T9 and TNK-TAR. Blast-1 was expressed by less than half the cases and Blast-2 and B5 by one of 12 cases each. This is in contrast to 10 non-CNS diffuse large cell lymphomas where B5 and Blast-1 were present on all cases. This study confirms previous observations that primary CNS large cell lymphomas are of B cell derivation. Moreover, the differences in expression of B cell activation antigens on CNS large cell lymphomas as compared to non-CNS lymphomas raise the possibility that a subset of neoplastic B cells may have unique tropism for the CNS.

Key words

lymphoma CNS lymphoma immunophenotype 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schaumberg HH, Plank CR, Adams RD: The reticulum cell sarcoma-microglioma group of brain tumors. A consideration of their clinical features and therapy. Brain 95: 199–212, 1972Google Scholar
  2. 2.
    Freeman C, Gerg JW, Cutter SG: Occurrence and prognosis of extranodal lymphoma. Cancer 29: 252–260, 1972PubMedGoogle Scholar
  3. 3.
    Fogelholm R, Uutela T, Murrows K: Epidemiology of central nervous system neoplasms. A regional survey in central Finland. Acta Neurol Scan 69: 129–136, 1984Google Scholar
  4. 4.
    Brain Tumor Registry of Japan. The Committee of Brain Tumor Registry in Japan. Kazuhiro Nomura, M.D., Chairman, Department of Neurosurgery National Cancer Center Hospital, Chua-Ku Tokyo 104, Japan 6: 1969, 1981Google Scholar
  5. 5.
    So YT, Beckstead JM, Davis RL: Primary central nervous system lymphoma in acquired immunodeficiency syndrome. A clinical and pathological study. Ann Neurol 20: 566–577, 1986Google Scholar
  6. 6.
    Hoover R, Fraumeni Jr JR: Risk of cancer in renal transplant recipients. Lancet 2: 55–57, 1973Google Scholar
  7. 7.
    Weintraub J, Warnke RA: Lymphomas in cardiac allotransplant recipients. Transplantation 33: 343–351, 1982Google Scholar
  8. 8.
    Helle TL, Britt RH, Colby TY. Primary lymphoma of the central nervous system. J Neurosurg 60: 94–103, 1984Google Scholar
  9. 9.
    Houthoff HJ, Poppema S, Ebels EJ, Elema JD: Intracranial malignant lymphomas. A morphologic and immunocytologic study of twenty cases. Acta Neuropathol (Berl) 44: 203–210, 1978Google Scholar
  10. 10.
    Taylor CR, Russell R, Lukes RJ, Davis RL: An immunohistological study of immunoglobulin content of primary central nervous system lymphomas. Cancer 41: 2197–2205, 1978Google Scholar
  11. 11.
    Letendre L, Banks PM, Reese DF, Miller RH, Scanlon PW, Kiely JM: Primary lymphoma of the central nervous system. Cancer 49: 939–943, 1982Google Scholar
  12. 12.
    Matsude M, McMurris M, Van Hale, Miller CA: CSF findings in primary lymphomas of the CNS. Arch Neurol 38: 397–402, 1981Google Scholar
  13. 13.
    Pearl GS, Chan WC, Bakay RAE, Wood JH: Primary lymphoma of the central nervous system diagnosed by computed tomography scan directed needle biopsy with frozen section immunoperoxidase technique. Neurosurgery 16: 1–4, 1985Google Scholar
  14. 14.
    Kumuanishi T, Washiyama K, Saito T, Nisdhyama A, Abe S Tanka T: Primary malignant lymphoma of the brain: An immunohistochemical study of eight cases using a panel of monoclonal and heterologous antibodies. Acta Neurpathol (Berl) 71: 190–196, 1986Google Scholar
  15. 15.
    Ernerudh J, Olsson T, Berlin G, Gustafsson B, Karkson M: Cell surface markers for diagnosis of central nervous system involvement in lymphoproliferative disease. Ann Neurol 20: 610–615, 1986Google Scholar
  16. 16.
    Jellinger K: Primary lymphomas of the CNS. Arch Neurol 39: 458–462, 1982Google Scholar
  17. 17.
    Ezrin-Waters C, Klein M, Deck J, Lang AE: Diagnostic importance of immunological markers in lymphomas involving the nervous system. Ann Neurol 16: 668–672, 1984Google Scholar
  18. 18.
    Li C-Y, Witzig TE, Phyliky RL, Zeismer SC, Yam LT: Diagnosis of B cell non-Hodgkin's lymphoma of the central nervous system by immunocytochemical analysis of cerebrospinal fluid lymphocytes. Cancer 57: 737–744, 1986Google Scholar
  19. 19.
    Li C-Y, Harrison EG: Histochemical and immunohistochemical study of diffuse large-cell lymphomas. Am J Clin Pathol 70: 721–732, 1978Google Scholar
  20. 20.
    Tubbs RR, Fishleder A, Weiss RA, Savage RA, Sebek BA, Weick JK: Immunohistochemical cellular phenotypes of lymphoproliferative disorders: Comprehensive evaluation of 564 cases including 257 non-Hodgkin's lymphomas classified by the International Workshop Formulation. Am J Pathol 113: 207–221, 1983Google Scholar
  21. 21.
    Aisenberg AC, Wilkes BM, Harris NL: Monoclonal antibody studies in non-Hodgkin's lymphoma. Blood 61: 461–475, 1983Google Scholar
  22. 22.
    Van der Valk P, Van den Besselaar-Dingjan G, Daha MR: Analysis of large cell lymphomas using monoclonal and hetrologous antibodies. J Clin Pathol 36: 44–50, 1985Google Scholar
  23. 23.
    Horning SJ, Doggert RS, Warnke RA: Clinical relevence of immunologic phenotype in diffuse large cell lymphoma. Blood 63: 1209–1215, 1984Google Scholar
  24. 24.
    Freedman AS, Boyd AW, Anderson KC, Fisher DC, Pinkus GS, Schlossman SF, Nadler LM: Immunologic heterogeneity of diffuse large cell lymphoma. Blood 65: 630–637, 1985Google Scholar
  25. 25.
    Freedman AS, Boyd AW, Berribe A, Horowitz JC, Levy DN, Rosen KJ, Baley J, Slaughenhoupt B, Levine H, Nadler LM: Expression of B cell activation antigens on normal and malignant B cells. Leukemia 1: 9–15, 1987.Google Scholar
  26. 26.
    Stashenko P, Nadler LM, Hardy R, Scholssman SF: Characterization of a human B. lymphocyte specific antigen. J Immunol 125: 1678–1685, 1980PubMedGoogle Scholar
  27. 27.
    Nadler LM, Stashenko P, Hardy R, Van Angthoven A, Terhorst C, Schlossman SF: Characterization of a B cell specific antigen (B2) distinct from B1. J Immunol 126: 1941, 1981Google Scholar
  28. 28.
    Boyd AW, Anderson KC, Freedman AS, Fisher DC, Slaughenhoupt BL, Schlossman SF, Nadler LM: Studies of in vitro activation and differentiation of human B lymphocytes I. Phenotypic functional characterization of the B cell population responding to anti-Ig antibody. J Immunol 134: 1516–23, 1985Google Scholar
  29. 29.
    Link MP, Bindle J, Meeker TC, Carswell C, Doss CA, Warnke RA, Levy R: A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol 137: 3013–3018, 1986Google Scholar
  30. 30.
    Nadler LM, Anderson KC, Marker G, Bates M, Park E, Daley JF, Schlossman SF: B4, a human B lymphocyte associated antigen expressed on normal mitogen activated, and malignant B lymphocytes. J Immunol 131: 244–254, 1983Google Scholar
  31. 31.
    Haynes B, Hemler BF, Cotner T, Mann DL, Eisenberth GS, Strominger JL, Fauci AS: Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation, J Immunol 127: 347–351, 1981Google Scholar
  32. 32.
    Haynes BF, Hemler ME, Mann DL, Eisenberth GS, Schelhamer J, Mostowski HS, Thomas CA, Strominger JL, Fauci AS: Characterization of a monoclonal antibody (4F2) that binds to human monocytes and a subset of activated lymphocytes. J Immunol 126: 1409–1414, 1981Google Scholar
  33. 33.
    Tsudo M, Uchiyama T, Uchino H: Expression of Tac antigen on activated normal B cells. J Exp Med 160: 612–618, 1984Google Scholar
  34. 34.
    Jung LKL, Hara T, Fu SM: Detection and functional studies of p60 65 (TAC antigen) on activated human B Cells. J Exp Med, 160: 1598–1604, 1984Google Scholar
  35. 35.
    Waldman TA, Goldman CK, Robb RJ, Depper JM, Leonard S, Sharrow O, Bongiovanni KF, Korsmeyer SJ, Greene WC: Expression of interleukin-2 receptors on activated human B cells, J Exp Med 160: 1450–1455, 1984Google Scholar
  36. 36.
    Boyd AW, Fisher DG, Fox D, Schlossman SF, Nadler LM: Structural and functional characterization of IL-2 receptors activated B cells. J Immunol 134: 387–392, 1985Google Scholar
  37. 37.
    Thorley-Lawson DA, Schooley RT, Ghan AK, Nadler LM: Epstein-Barr virus superinduces a new human B cell differentiation antigen (Blast-1) expressed on transformed lymphoblasts. Cell 30: 415–425, 1985Google Scholar
  38. 38.
    Freedman AS, Boyd AW, Anderson KC, Fisher DC, Schlossman SF, Nadler LM: B5 a new B cell restricted antigen. J Immunol 134: 2238–2235, 1985Google Scholar
  39. 39.
    Thorley-Lawson DA, Nadler LM, Bhan AK, Schooley RT: Blast-2 (EBVCS) an early cell surface marker on human B cell activation is superinduced by Epstein-Barr virus. J Immunol 134: 3007–3012, 1985Google Scholar
  40. 40.
    Yokochi T, Holly RD, Clark EA: Lymphoblast antigen (BB1) expressed on Epstein-Barr virus infected B cell blasts: B lymphoblastoid cell lines and Burkitt's lymphoma. J Immunol 128: 823–827, 1982Google Scholar
  41. 41.
    Haynes BF: Summary of T cell studies performed during the Second International Workshop and Conference on Human Leukocyte Differentiation Antigens. Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, Eds. Leukocyte Typing II, Vol 3. New York Springer Verlag 1–25, 1986Google Scholar
  42. 42.
    Neckers LM, Yenokidu G, James SP: The role of the transferrin receptor in human B leukocyte activation. J Immunol 133: 2437–2441, 1984Google Scholar
  43. 43.
    Nicholson GL, Windelhaken JL: Organ specificity of blood-borne tumor metastasis determined by cell adhesion. Nature 255: 230–232, 1975PubMedGoogle Scholar
  44. 44.
    Picker LJ, Medeiros LH, Weiss LM, Warnke RA, Butcer EC: Expression of lymphocyte norming receptor antigen in non-Hodgkin's lymphoma. Am J Pathol 130: 496–504, 1988Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • R. Bashir
    • 1
  • A. Freedman
    • 3
  • N. Harris
    • 2
  • K. Bain
    • 1
  • L. Nadler
    • 3
  • F. Hochberge
    • 1
  1. 1.Division of NeurologyUniversity of Nebraska Medical CenterUSA
  2. 2.Departments of Neurology and PathologyMassachusetts General HospitalUSA
  3. 3.Division of Tumor ImmunologyDana Farber Cancer InstituteUSA

Personalised recommendations